0001209191-20-042311.txt : 20200713 0001209191-20-042311.hdr.sgml : 20200713 20200713185459 ACCESSION NUMBER: 0001209191-20-042311 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200709 FILED AS OF DATE: 20200713 DATE AS OF CHANGE: 20200713 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Barth Jay CENTRAL INDEX KEY: 0001601896 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 201026016 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS, INC. STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-09 0 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001601896 Barth Jay C/O AMICUS THERAPEUTICS, INC. 1 CEDAR BROOK DRIVE CRANBURY NJ 08512 0 1 0 0 Chief Medical Officer Common Stock 2020-07-09 4 M 0 11559 8.61 A 174763 D Common Stock 2020-07-09 4 M 0 8850 9.03 A 183613 D Common Stock 2020-07-09 4 M 0 6142 10.04 A 189755 D Common Stock 2020-07-09 4 M 0 17896 12.28 A 207651 D Common Stock 2020-07-09 4 S 0 44447 15.9177 D 163204 D Common Stock 2020-07-10 4 M 0 28843 5.13 A 192047 D Common Stock 2020-07-10 4 S 0 28843 15.6514 D 163204 D Common Stock 20 I By Daughter Stock Options (right to buy) 8.61 2020-07-09 4 M 0 11559 0.00 D 2025-01-02 Common Stock 11559 0 D Stock Options (right to buy) 9.03 2020-07-09 4 M 0 8850 0.00 D 2026-01-04 Common Stock 8850 0 D Stock Options (right to buy) 10.04 2020-07-09 4 M 0 6142 0.00 D 2029-01-02 Common Stock 6142 55099 D Stock Options (right to buy) 12.28 2020-07-09 4 M 0 17896 0.00 D 2025-06-01 Common Stock 17896 0 D Stock Options (right to buy) 5.13 2020-07-10 4 M 0 28843 0.00 D 2027-01-03 Common Stock 28843 11778 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.90 to $15.98. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.49 to $15.91 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. All of the options were fully vested and exercisable as of the transaction date. As of July 9, 2020, 9,584 options were fully vested and exercisable and 51,657 remained unvested from this grant. As of July 10, 2020, 31,785 options were fully vested and exercisable and 8,836 remained unvested from this grant. /s/ Christian Formica, Attorney-in-Fact 2020-07-13